Grifols SA (GRFS): what the price assumes

boothcheck covers Grifols SA (GRFS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/GRFS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.1%); the inversion above states its own rate.

Per-Model Detail (n=15)

Solvency

Bullet Takeaways

• The valuation methods disagree sharply. The relative and EV/EBITDA methods land far above the $7.39 price near $17 to $26, while the asset-based and earnings-power methods land far below near $1 to $4, leaving the central blended read near $8.32.
• The turnaround is in the numbers: first-quarter revenue rose 3.3% at constant currency to roughly €1.7 billion, net profit climbed about 22% to €73 million, and immunoglobulins grew 15.3%, with adjusted EBITDA margin around 22.4%.
• The defining constraint is debt. Net leverage of about 4.3x and interest coverage near 1.6x mean the deleveraging plan, helped by the refinancing of all 2027 maturities and recent rating upgrades, is what governs the equity outcome.

Bull Case

Grifols is best understood through a sector-specific lens, because plasma-derived medicine is a business with unusual economics that generic valuation frames handle poorly. Collecting human plasma and fractionating it into immunoglobulins, albumin, and clotting factors is capital-intensive, vertically integrated, and protected by a scarce input, donor plasma, and by demanding regulatory approval of each collection center and product. That structure creates a wide moat for the handful of global players, and it means the right way to value Grifols is on its earnings power and cash generation as the plasma volumes ramp, not on its book value or a single multiple. The first quarter showed that engine running: revenue rose 3.3% at constant currency to about €1.7 billion, biopharma revenue grew 6.8%, and immunoglobulins, the highest-value product line, grew 15.3%. Demand for immunoglobulin therapies is structurally growing, and Grifols is one of the few companies that can supply it at scale.

The profitability and the deleveraging are moving in the right direction together. Adjusted EBITDA reached about €381 million at a 22.4% margin, and management is guiding to a full-year adjusted EBITDA margin of at least 25%, with 5% to 9% EBITDA growth and free cash flow of €500 million to €575 million. That free-cash-flow target is the crux of the bull case, because it is what pays down the debt that has weighed on the equity. Net leverage improved to about 4.3x from 4.5x, the company refinanced all of its 2027 debt maturities, and it earned rating upgrades from S&P, Moody's, and Fitch, all of which lower the cost of capital and reduce the refinancing risk that has been the central worry.

The methods that can price the earnings power suggest meaningful upside if the plan holds. The relative valuation method lands near $17.57, the EV/EBITDA method near $26.25, and the exit-multiple DCF near $15.26, all well above the $7.39 price (June 27, 2026). New management under CEO Nacho Abia is focused on commercial execution, the ramp of Egypt as a plasma-sourcing platform after European Medicines Agency approval, and continued balance-sheet repair. For a buyer who believes the immunoglobulin demand and the free-cash-flow conversion are durable, the equity is a leveraged call on a deleveraging, structurally advantaged plasma franchise, and the relative multiples say the upside is large.

Bear Case

The bear case is cleanest when framed around the disagreement among the valuation methods, because that disagreement is itself the warning. The methods split into two camps. The relative and EV/EBITDA methods, which assume Grifols deserves a full sector multiple on its revenue and EBITDA, land at $17 to $26. The asset-based and earnings-power methods, which anchor to book value and to the cash the business actually earns after its heavy interest burden, land at $1 to $4. When the optimistic methods say a stock is worth three times what the conservative methods say, the conservative ones are usually the more honest read, because they are not extending credit for a recovery that has not yet been delivered. The earnings-power value near $1.09 and the residual-income value near $1.56 are telling you that, after the debt, the business is not yet earning enough to justify a price far above its troubled book.

The reason the conservative methods are the right anchor is the balance sheet. Net leverage of about 4.3x and interest coverage near 1.6x mean a large share of operating earnings goes to servicing debt rather than to equity holders, and at that level of leverage small disappointments in EBITDA or free cash flow are amplified into large swings in the equity. The refinancing of the 2027 maturities removed a near-term cliff, but it did not reduce the absolute debt load; it bought time. If the guided free cash flow of €500 million to €575 million falls short, the deleveraging stalls, the rating upgrades reverse, and the cost of capital rises again, which is exactly the scenario the relative methods ignore.

There is also a governance overhang that compounds the financial risk. Grifols has a complex ownership and board structure, has faced scrutiny over related-party transactions and accounting in the past, and continues to reshape its board, with a director resignation and new appointments as recently as June 2026. For a highly leveraged company, governance quality is not a side issue; it determines whether minority holders of the non-voting ADR share are treated fairly when capital decisions are made. If the deleveraging disappoints or governance concerns resurface, the stock has room to fall toward the methods that anchor to current, after-interest reality.

Valuation

The signature of Grifols' X-ray is dispersion, and the dispersion maps directly to the central debate. The optimistic methods, which credit a full sector multiple, land high: the relative valuation method near $17.57, the EV/EBITDA method near $26.25, the price-to-sales method near $46, and the exit-multiple DCF near $15.26. The conservative methods, which anchor to book value and after-interest earnings, land low: the earnings-power value near $1.09, residual income near $1.56, and the two-stage excess-return method near $2.12. A middle group, the Peter Lynch method near $8.32, the Graham number near $8.80, and the Ben Graham formula near $8.07, lands close to the price, and the central blended read is about $8.32, just above the $7.39 price.

The inverted view characterizes the price as justified by relative-multiple and growth-DCF, with asset-based and earnings-power methods saying expensive. The key interpretive point is which of those frames to trust. For a company at 4.3x net leverage with 1.6x interest coverage, the methods that account for the debt service, the earnings-power and asset methods, are the more honest read, because they reflect what actually reaches equity holders after the creditors are paid. The relative methods assume the leverage and the discount both melt away as the turnaround completes.

The honest synthesis is that this is a leveraged turnaround whose fair value depends entirely on whether you believe the deleveraging completes. If the free-cash-flow guidance is met and net leverage keeps falling, the relative methods near $15 to $26 become the right frame and the equity is deeply undervalued. If the deleveraging stalls, the conservative methods near $1 to $4 reassert themselves and the current price proves too high. The blended read near $8.32 sits in between, reflecting genuine uncertainty. The stock is a bet on execution of a debt-reduction plan in a structurally advantaged but capital-heavy industry, with governance risk on top, and the price already leans toward the optimistic side of the method spread.

Catalysts

The dominant catalyst is free-cash-flow generation and deleveraging, with management guiding to €500 million to €575 million of free cash flow and a full-year adjusted EBITDA margin of at least 25%; meeting those targets is what reduces net leverage from the current 4.3x and validates the optimistic valuation methods. The 2027 refinancing and the recent rating upgrades from S&P, Moody's, and Fitch are concrete catalysts that lower the cost of capital and remove a near-term maturity cliff. Immunoglobulin demand is the key revenue driver, having grown 15.3% in the quarter, and continued share gains in that high-value product line support the EBITDA ramp. The Egypt plasma-sourcing platform, approved by the European Medicines Agency, is a forward catalyst that expands the supply of the scarce input the whole business depends on. Governance is a two-sided catalyst: the ongoing board refresh, including a director resignation and new appointments in June 2026, will either reassure or unsettle minority holders depending on how it unfolds. Sentiment is cautiously positive, with a Buy-leaning consensus and an ADR target near $11, above the current price, so demonstrated progress on cash flow and leverage is what would close the gap, while any free-cash-flow miss would reopen the debt concerns.

Sources: TipRanks Q1, Grifols press release, TipRanks governance, MarketScreener consensus

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• SOLV (SOLVENTUM CORPORATION)
• FY2025 10-K: …and Align Technology, which competes with only orthodontic solution offerings. The health care software technology market in which we conduct our business, and the healthcare information technology ("HCIT") industry in general, is highly competitive and dynamic, characterized by the continual introduction of new…
• FY2025 10-K: …adoption of our Solventum™ 360 Encompass TM and performance management solutions. • Clinician productivity solutions declined primarily due to impacts from changing market conditions. • Foreign currency translation positively impacted sales by 0.2%. Business segment operating income margin increased when compared to…
• ICLR (ICON plc)
• FY2025 20-F: …Collectively, our business development team, senior executives and project team leaders share responsibility for client relationships. Our aim is to be a preferred partner to our clients, to help them achieve their goals, and for ICON to gain repeat business and cross-sell additional service lines. Competition The…
• FY2025 20-F: …The failure to enter strategic partnership arrangements with customers or the loss of existing customers as a result of them entering strategic partnership arrangements with our competitors could have a material adverse impact on our results of operations. Increased collaboration amongst pharmaceutical companies in…
• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …markets and market those products profitably. For example, in the past we have experienced elevated charges for excess and obsolete inventory while also facing increased backorders due to unpredictable demand fluctuations across our various markets, and there can be no assurance that production mix planning or…
• FY2025 10-K: …for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc. There are smaller competitors in these product categories as well that focus on smaller subsegments of the…
• ZTS (Zoetis Inc.)
• FY2025 10-K: …of all potential risks or uncertainties. Risks related to our business and the animal health industry The animal health industry is highly competitive. We believe many of our competitors are conducting R&D activities in areas served by our products and in areas in which we are developing products. Our competitors…
• FY2025 10-K: …are expected to be approximately $ 243 million in 2026 and $ 184 million thereafter. 19. Segment Information A. Segment Information We manage our operations through two geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a…
• BIIB (BIOGEN INC.)
• FY2025 10-K: …of HI-Bio, the underperformance or discontinuation of one or more marketed, preclinical or clinical programs, recruitment by competitors or changes in the overall labor market. Changes in our organizational structure or in our flexible working arrangements could also impact productivity and morale as well as our…
• FY2025 10-K: …performance; • our long-term strategy and supporting business plans, including our product pipeline; • our expectations about growth through acquisitions and key collaborative relationships and funding arrangements; • our belief that our long-term competitive position depends upon our success in discovering and…
• SNN (Smith & Nephew plc)
• FY2025 20-F: …towards the end of 2024. Orthopaedics revenue grew by 4.1% (and 4.6% on an underlying1 basis) driven by strong performance in Other Established Markets2 as well as significant improvement in the US as the year progressed, partially offset by headwinds in China due to lower end customer demand. We continued to hold a…
• FY2025 20-F: …5.3% on an underlying1 basis excluding a 80bps tailwind from foreign exchange, with all business units contributing to the year-on-year growth. All three business units delivered underlying1 growth above 5%, contributing to the overall year-on-year revenue growth. We continued to make progress in improving the…
• OGN (Organon & Co.)
• FY2025 10-K: …to make such pivot effectively, or a failure to develop and maintain a presence in China or emerging markets could adversely affect our business, cash flow, results of operations, financial condition or prospects. We face intense competition from competitors' products. Our products face intense competition from…
• FY2025 10-K: …rights are increasingly being challenged by competitors and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge…
• STE (STERIS plc)
• FY2025 10-K: …to outsourced instrument reprocessing services. In addition, our procedural products also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment supports medical…
• FY2025 10-K: …volume. Life Sciences revenues decreased 5.1% in fiscal 2025, as compared to fiscal 2024 partially due to the sale of the CECS business, which more than offset other services growth resulting in a decline of 16.1% in service revenues. This decrease also reflects declines in capital equipment revenues of 24.4%, which…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.